

Sheet 1 OF 14

Figure 1




Sheet 2 OF 14

Figure 2




Sheet 3 OF 14

Figure 3




Sheet 4 OF 14

Figure 4



Sheet 5 OF 14

Figure 5




Title: Porphyrin-Polyamine Conjugates for Cancer Therapy

Inventor(s): Benjamin FRYDMAN, et al Application No.: Not yet assigned Docket No.: 376462001700


Sheet 6 OF 14

Figure 6



Sheet 7 OF 14

Figure 7




Title: Porphyrin-Polyamine Conjugates for Cancer Therapy Inventor(s): Benjamin FRYDMAN, et al

Inventor(s): Benjamin FRYDMAN Application No.: Not yet assigned Docket No.: 376462001700

Sheet 8 OF 14

Figure 8




Title: Porphyrin-Polyamine Conjugates for Cancer Therapy Inventor(s): Benjamin FRYDMAN, et al

Application No.: Not yet assigned Docket No.: 376462001700


Sheet 9 OF 14

Figure 9




Sheet 10 OF 14

Figure 10




Sheet 11 OF 14

Figure 11




Sheet 12 OF 14

Figure 12



Sheet 13 OF 14

Figure 13




Title: Porphyrin-Polyamine Conjugates for Cancer Therapy

Inventor(s): Benjamin FRYDMAN, et al Application No.: Not yet assigned Docket No.: 376462001700

Sheet 14 OF 14

Oral 11237

Figure 14



male athymic nude mice were given s.c. injections of 0.75 x10⁶ DU145 cells on Day 0. beginning on Day 10 mice were treated once weekly for 3 weeks with acidified water, 100mg/kg or 500mg/kg SL-237 via oral gavage at 10 ml/kg dosing volume.

^{*} The 3rd treatment was actually 400mg/kg in the high dose group.